PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Co.'s extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. PRF-110, Co.'s first product candidate, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. We show 2 historical shares outstanding datapoints in our PRFX shares outstanding history coverage, used to compute PRFX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PRFX market cap history over the course of time is important for investors
interested in comparing PRFX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PRFX versus a peer is one thing; comparing
PRFX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PRFX can fluctuate over the course of history.
With this page we aim to empower investors researching PRFX by allowing them to research the PRFX market cap history. |
Free PRFX Email Alerts:
Video: The Importance of Market Cap
